Dr. Agarwal’s Health Care Limited announced a robust financial performance for the period ending December 31, 2025. Total Income increased by 20.8% to ₹1,548 Cr, with EBITDA reaching ₹440 Cr and Profit After Tax at ₹118 Cr. The company expanded its network to 272 eye care facilities, including 38 new additions during the period.
Financial Highlights
Dr. Agarwal’s Health Care Limited reported significant financial growth for the nine months ending December 31, 2025:
- Total Income: Increased by 20.8% year-over-year to ₹1,548 Cr.
- EBITDA: Reached ₹440 Cr, representing a 23.6% year-over-year growth.
- Profit After Tax: Stood at ₹118 Cr, a substantial 74.3% increase compared to the previous year.
Operational Performance
The company also demonstrated strong operational growth:
- Eye Care Facilities: Expanded to 272 facilities, a net increase of 38 facilities.
- Patients Served: Over 2.2 million patients were served.
- Surgeries Performed: Over 238,000 surgeries were performed.
- Doctors: Employs 908 doctors and 2,052 paramedics.
Geographic Footprint
Dr. Agarwal’s has a strong presence in India, with 90.1% of its revenue coming from domestic operations. The company operates across 14 states and 5 Union Territories within India and is expanding its presence in Africa, which contributes 9.9% to its revenue. They have facilities across 148 cities.
Expansion Plans
The company plans to add 53 facilities in the upcoming quarter, further solidifying its market presence.
Revenue Mix
The revenue mix is primarily driven by Surgeries, which constitute 65.1% of the revenue, followed by Diagnosis, Consultations, & Others at 14.3%, and Opticals, Contact Lens, and Accessories at 12.9%. Eye Care Related Pharma Products account for the remaining 7.7%.
Awards and Recognition
The announcement also highlighted the recognition received by doctors including awards at MOSCON and YOSI, and the OPL Trophy at the American Academy of Ophthalmology (AAO) 2025.
Source: BSE
